ArticleBMC psychiatry2025
Global mortality, prevalence and disability-adjusted life years of Alzheimer's disease and other dementias in adults aged 60 years or older, and the impact of the COVID-19 pandemic: a comprehensive analysis for the global burden of disease 2021.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The role of AI-assisted drug repurposing in neurological disorders: a systematic review of validation strategies, challenges and opportunities.Journal of nanobiotechnology · 2026Pooled it
- A survey of deep learning techniques in detecting neurological disorders using MRI.Biomedical engineering online · 2026Pooled it
- Mechanism and progress of deep brain stimulation in the treatment of neurological and psychiatric disorders.MedScience · 2026Review
- The growing burden of dementia in Asia: Comparative insights from Japan, China, and India.The journal of prevention of Alzheimer's disease · 2026Article
- Translational potential of medicinal plants for Alzheimer's disease: integrated evidence from molecular mechanisms to preclinical and clinical findings.Natural products and bioprospecting · 2026Review
- Epigenetic Regulation of Modulatory Neurotransmitter System Integrity in the Aging Brain: A Scoping Review Across the Lifespan.Life (Basel, Switzerland) · 2026Review
- Joint Trajectories of Frailty and Cognitive Function in Older Koreans Based on 14-Year Period Data From Korean Longitudinal Study of Aging (KLoSA).Geriatrics & gerontology international · 2026Article
- Micro- and Nanoplastics in the Human Brain: Mechanistic Plausibility, Translational Challenges, and Links to Neurological Disease Trends.Molecular neurobiology · 2026Review
- CRISPR-Cas9 and next-generation gene editing strategies for therapeutic intervention of neurodegenerative pathways in Alzheimer's disease: a state-of-the-art review.Acta neurologica Belgica · 2026Review
- Global, regional and national prevalence of mental disorders among women at childbearing age from 1992 to 2021.Archives of women's mental health · 2026Article
- A Global, Regional, and National Survey on Burden and Quality of Care Index of Alzheimer's Disease and Other Dementias in Adults Aged 55 and Above: The Global Burden of Disease Study 1990-2021.Neuroepidemiology · 2026Article
- Oral Dysbiosis and Neuroinflammation: Implications for Alzheimer's, Parkinson's and Mood Disorders.Microorganisms · 2026Review
- Multi-platform integration of brain and CSF proteomes reveals biomarker panels for Alzheimer's disease.Briefings in bioinformatics · 2026Article
- Aildenafil citrate with superior PDE5 selectivity ameliorates cognitive and behavioral impairments in APP/PS1 Alzheimer's disease mice: a preclinical phenotypic study.Frontiers in pharmacology · 2026Article
- Community-based solutions: a principles-to-practice framework to support individuals living with dementia and their care partners.Innovation in aging · 2026Review
- Modeling Alzheimer's disease with brain organoids: mechanisms, applications, and future directions.Frontiers in cell and developmental biology · 2026Review
- Evaluating the cognitive efficacy of marine-derived drugs in Alzheimer's disease: A systematic review and Bayesian network meta-analysis.Therapeutic advances in neurological disorders · 2026Article
- Qifuyin improves physiological frailty by regulating the intestinal flora in 3xTg-AD mice.Frontiers in microbiology · 2026Article
- The active construction of past episodes.Translational neuroscience · 2026Article
- Conformationally locked 7-aryl tetrahydroisoquinolines as dual acetylcholinesterase inhibitors and antioxidants: role of intramolecular hydrogen bonding and aryl electronics.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAlzheimer's disease (AD) and other dementias are major public health concerns with an increasing global impact. The burden of these conditions varies by region, age, and gender, and the COVID-19 pandemic has further exacerbated these disparities, potentially influencing disease prevalence, mortality, and disability burden. This study aimed to assess the global and regional burden and trends of Alzheimer's disease and other dementias in adults aged 60 years or older from 1990 to 2021, with a particular focus on the impact of the COVID-19 pandemic on mortality, prevalence, and disability-adjusted life years.
methodsUsing Global Burden of Disease (GBD 2021) data, we analyzed age-standardized death rates (ASDR), incidence rates (ASIR), prevalence rates (ASPR), and disability-adjusted life years (DALYs) from 1990 to 2021. Temporal trends were assessed using the Estimated Annual Percentage Change (EAPC). Projections were modeled using Bayesian Age-Period-Cohort (BAPC) techniques. We evaluated excess mortality by comparing actual versus expected deaths during the pandemic. Decomposition analysis examined the contributions of population growth, aging, and epidemiological shifts. We analyzed health inequality to highlight and address disparities in health status and resource access across regions. All plots and tables were created using Joinpoint Regression model (Version 4.8.0.1), StataMP 18, and R statistical packages (Version 4.4.1).
resultsIn 2021, global mortality from AD and other dementias among individuals aged 60 and older reached approximately 1,922,970.75 cases (95% CI: 480,348.08 to 5,104,315.95), and the prevalence was 52,560,253.51 cases (95% CI: 41,399,948.84 to 65,633,448.71). High Body Mass Index (BMI) and High Fasting Plasma Glucose (FPG) were prominent risk factors. Projections suggest a near fourfold increase in AD cases by 2050, driven by population growth and aging, with females disproportionately affected. Health inequalities persist, with higher disease burdens in high-SDI regions. The pandemic impacted mortality unevenly, highlighting regional disparities.
conclusionAlthough incidence rates declined from 1990 to 2021, the overall burden of AD and dementias remains substantial and is expected to rise significantly by 2050. The findings underscore the need for targeted interventions addressing risk factors like High FPG, gender disparities, and the socioeconomic effects of COVID-19, particularly in high-SDI countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.